Earnings results for Avidity Biosciences (NASDAQ:RNA)
Avidity Biosciences, Inc. is estimated to report earnings on 03/02/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.32.
Analyst Opinion on Avidity Biosciences (NASDAQ:RNA)
4 Wall Street analysts have issued ratings and price targets for Avidity Biosciences in the last 12 months. Their average twelve-month price target is $43.33, predicting that the stock has a possible upside of 79.58%. The high price target for RNA is $60.00 and the low price target for RNA is $34.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Avidity Biosciences has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $43.33, Avidity Biosciences has a forecasted upside of 79.6% from its current price of $24.13. Avidity Biosciences has received no research coverage in the past 90 days.
Dividend Strength: Avidity Biosciences (NASDAQ:RNA)
Avidity Biosciences does not currently pay a dividend. Avidity Biosciences does not have a long track record of dividend growth.
Insiders buying/selling: Avidity Biosciences (NASDAQ:RNA)
In the past three months, Avidity Biosciences insiders have not sold or bought any company stock. 72.02% of the stock of Avidity Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Avidity Biosciences (NASDAQ:RNA
Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($1.53) to ($1.66) per share.
More latest stories: here